# Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer

> **NCT03957564** · PHASE2 · UNKNOWN · sponsor: **Affiliated Hospital of Qinghai University** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Cancer
- Gastro-oesophageal Junction Cancer

## Interventions

- **DRUG:** Neoadjuvant chemotherapy with PSOX regimen.
- **OTHER:** Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.
- **OTHER:** Detect the tumor related DNA in pathological tissues after operation.
- **OTHER:** Follow-up of DFS and OS in patients with gastric cancer after operation.

## Key facts

- **NCT ID:** NCT03957564
- **Lead sponsor:** Affiliated Hospital of Qinghai University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-28
- **Primary completion:** 2022-05-20
- **Final completion:** 2024-05-20
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03957564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03957564, "Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03957564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*